Addex (ADXN) Reports Q2 2026 Financials and Provides Clinical Development Updates
Addex Therapeutics reported its financial results for the first half of 2026, showing a net loss of CHF 3.5 million and an operating loss of CHF 1.1 million. The company's cash reserves stood at CHF 767,000 as of June 30, down from CHF 1.6 million in December 2025 due to ongoing operational costs. Addex raised USD 2.8 million through a capital raise between July and August 2026, extending its cash runway into Q4 2027. The company regained full global rights for the GABAB PAM portfolio after Indivior's merger with Supernus Pharmaceuticals. Clinical updates included progress on NTX-253, expected to complete Phase 1 trials in late 2026, and Dipraglurant repositioning efforts targeting post-stroke recovery through a collaboration with Lund University and Syntxis.
Tickers: $ADXN
Topics: capital raise cash position clinical development equity investment net loss operating loss